Kapiva secures $60 million to boost R&D, health-tech, and global expansion

Kapiva, the modern Ayurveda brand, has raised over $60 million in a fresh funding round backed by 360 One Asset and Vertex Growth. The company plans to deploy the capital towards strengthening research and development, health-tech initiatives, manufacturing, and expanding its global presence.

Ameve Sharma, Founder of Kapiva, told CNBC-TV18 that the round was a milestone for the company as it helped complete a full investor cycle. “The majority of the round was actually secondary, where we exited some of our early investors and angels. This itself was a very good milestone for the organisation, because going through a complete investor cycle… puts it on its way to becoming a later stage company,” he said.

The company, which has built an annual recurring revenue of over ₹550 crore with 80% year-on-year growth, is focused on combining traditional Ayurveda with modern scientific methods. “The vision for the organisation is, how do we combine authentic, traditional, high-quality Ayurveda with newer scientific methods and standardisation? Bringing in things like clinical validation, standardising on a molecular level, to deliver measurable benefit to our customers,” Sharma said.

Kapiva has tied up with leading allopathic hospital chains, research institutions such as AIIMS, and government bodies like CSIR to clinically validate its products. Sharma believes this will help Ayurveda gain mainstream acceptance. “There’s no reason why Ayurvedic products, once manufactured correctly, cannot deliver measurable efficacy—maybe not as quickly as allopathy, but over a period of time, as effective as allopathy,” he explained.

The company’s diabetes and sports nutrition supplements currently contribute around 60% of its revenue, with each nearing ₹200 crore in sales. Sharma also sees potential in heart and liver health categories as the brand expands its portfolio.

While India remains its largest market, Kapiva is looking abroad to accelerate growth. The company has subsidiaries in Dubai and the US, and is expanding in Europe with the UK and Germany showing early traction. Global business contributes about 10% of revenues but is the fastest-growing segment.

At home, the company is pursuing an omnichannel strategy. Kapiva is already present in 50,000 stores and aims to scale that number to one lakh by March 2026. Alongside offline growth, its digital platforms are also gaining momentum, with 35% of business coming from its app and website, which also provide doctor consultations and diet plans.

Kapiva is also one of the largest supplement sellers on Amazon and Flipkart, underscoring its strong play in the e-commerce channel. Sharma’s long-term vision is clear: “It’s still very early days for scientific Ayurveda to actually become mainstream in India. My vision is to see this as a multi-billion-dollar global healthcare brand.”

Watch accompanying video for full show.Read about our editorial guidelines and ethics policy